Skip to content

US · ACB · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Aurora Cannabis Inc. (ACB) intrinsic value and stock valuation

$4.16as of 2026-11-21 · Mkt cap 180.25M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Aurora Cannabis Inc. DCF and intrinsic value

InvestorsCraft values ACB with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ACB’s statements →

Aurora Cannabis Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Edmonton, AB T6X 1V8 auroramj.com

How the business is doing

Fiscal 2012–2026, USD

Revenue
$320.6M+5.5% 5y CAGRd
20122026
Net income
-$-121.76M
20122026
Free cash flow
-$-36.06M
20122026
Total equity
$513.2M-24.1% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2026, USD
20262025202420232022
Revenue$320.6M$343.3M$270.3M$223.8M$221.3M
Operating income-$-46.66M$4.95M-$-46.45M-$-207.19M-$-231.45M
Net income-$-121.76M$1.59M-$-69.33M-$-816.63M-$-1.74B
EPSd-$-2.12M$28.5K-$-1.35M-$-25.31M-$-80.93M
Operating cash flow-$-13.51M$16M-$-68.51M-$-115.82M-$-110.27M
Capital expenditure-$-22.55M-$-18.86M-$-16.83M-$-12.13M-$-32.21M
Free cash flow-$-36.06M-$-2.85M-$-85.34M-$-127.95M-$-142.48M
Total assets$602.6M$847.8M$840.1M$926.4M$926.4M
Total debt$23.9M$104M$99.8M$226.4M$226.4M
Net debt-$-88.85M-$-80.28M-$-79.75M-$-74.45M-$-74.45M
Total equity$513.2M$605.1M$602.9M$521.7M$521.7M
Cash and short-term investments$165.1M$184.8M$183.6M$300.9M$300.9M
Income statement
20262025202420232022
Revenue$320.6M$343.3M$270.3M$223.8M$221.3M
Cost of revenue$183.9M$155.7M$138.8M$209M$200.1M
Gross profit$136.7M$187.6M$131.5M$14.8M$21.2M
Research and development expenses$4.02M$3.68M$3.57M$5.77M$10.4M
Selling, general and administrative expenses$166.2M$166.5M$156.9M$170.5M$189M
Other expenses$13.1M$12.5M$17.5M$45.7M$53.3M
Operating expenses$183.3M$182.7M$177.9M$222M$252.7M
Cost and expenses$367.3M$338.4M$316.7M$431M$452.8M
Interest income$5.85M$11.5M$12.8M$19M$4.51M
Interest expense$1.81M$8.42M$14.2M$39.5M$71.8M
Depreciation and amortization$3.81M$22.6M$33.1M$52.6M$93.7M
Ebitda-$-50.9M$51.4M-$-12.34M-$-135M-$-1.55B
Operating income-$-46.66M$4.95M-$-46.45M-$-207.19M-$-231.45M
Total other income/expenses, net-$-9.86M$15.4M-$-13.15M-$-576.51M-$-1.49B
Income before tax-$-56.52M$20.4M-$-59.6M-$-783.7M-$-1.72B
Income tax expense$2.1M$4.62M-$-550K$16.6M-$-2.14M
Net income-$-121.76M$1.59M-$-69.33M-$-816.63M-$-1.74B
Weighted average shares outstanding$56.7M$54.9M$51.3M$32.3M$21.5M
Weighted average diluted shares outstanding$57.3M$55.8M$51.3M$32.3M$21.5M
Balance sheet
20262025202420232022
Cash and short-term investments$165.1M$184.8M$183.6M$300.9M$300.9M
Net receivables$44.7M$42.2M$45.5M$41.4M$41.4M
Inventory$175.5M$237.7M$186.7M$128.8M$128.8M
Total current assets$398.5M$475.6M$427.4M$480M$480M
Property, plant and equipment, net$124M$266.6M$294.8M$323M$323M
Goodwill and intangible assets$58.2M$88.5M$84.2M$78.4M$78.4M
Long-term investments$15.8M$5.23M$6.35M$13.8M$13.8M
Total non-current assets$204.2M$372.2M$412.8M$446.4M$446.4M
Total assets$602.6M$847.8M$840.1M$926.4M$926.4M
Accounts payable$9.33M$27.5M$20.4M$21.9M$21.9M
Short-term debt$5.74M$26.7M$57.3M$147.6M$147.6M
Deferred revenue$1.27M$1.07M$1.69M$1.74M$1.74M
Total current liabilities$67.1M$110.2M$124.8M$237.8M$237.8M
Long-term debt$18.2M$77.2M$42.5M$78.8M$78.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$22.4M$132.5M$112.4M$166.9M$166.9M
Capital lease obligations$18.2M$37.3M$37.6M$42.7M$42.7M
Total liabilities$89.5M$242.7M$237.2M$404.6M$404.6M
Common stock$7.03B$6.95B$6.98B$6.84B$6.84B
Retained earnings-$-6.46B-$-6.33B-$-6.38B-$-6.29B-$-6.29B
Accumulated other comprehensive income (loss)-$-214.15M-$-55.91M-$-43.78M-$-58.33M-$-58.33M
Total equity$513.2M$605.1M$602.9M$521.7M$521.7M
Total investments$68.2M$5.78M$10.4M$13.8M$13.8M
Total debt$23.9M$104M$99.8M$226.4M$226.4M
Net debt-$-88.85M-$-80.28M-$-79.75M-$-74.45M-$-74.45M
Cash flow statement
20262025202420232022
Net income-$-58.62M$15.8M-$-57.08M-$-265.33M-$-1.72B
Depreciation and amortization$14.2M$22.6M$32.8M$43.6M$93.7M
Stock-based compensation$7.29M$11.5M$12.7M$16.9M$13.8M
Change in working capital-$-9.21M$10.2M-$-15.54M-$-25.12M$52.7M
Accounts receivable-$-8.15M$5.24M-$-4.5M$5.53M$18.3M
Inventory$7.44M-$-15.05M$3.87M$49M$21.1M
Accounts payable-$-8.04M$14.9M-$-15.7M-$-8.06M$6.76M
Net cash provided by operating activities-$-13.51M$16M-$-68.51M-$-115.82M-$-110.27M
Investments in property, plant and equipment-$-22.55M-$-18.86M-$-16.83M-$-12.13M-$-32.21M
Acquisitions, net$0.00$0.00-$-5.54M-$-18.54M-$-23.42M
Net cash used for investing activities-$-72.61M-$-14.33M-$-3.36M-$-27.29M-$-36.17M
Common stock issued$11.5M$820K$37.9M$73.2M$350.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$9.76M-$-120K-$-47.92M-$-56.48M$147.8M
Net change in cash-$-73.23M$1.83M-$-119.5M-$-140.01M$16.4M
Cash at end of period$64.7M$137.9M$136.1M$300.8M$437.8M
Operating cash flow-$-13.51M$16M-$-68.51M-$-115.82M-$-110.27M
Capital expenditure-$-22.55M-$-18.86M-$-16.83M-$-12.13M-$-32.21M
Free cash flow-$-36.06M-$-2.85M-$-85.34M-$-127.95M-$-142.48M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Aurora Cannabis Inc.

        Aurora Cannabis Inc. is a leading company in the global cannabis industry, focusing on the cultivation, production, and sale of various cannabis and cannabis-derived products across Canada and internationally. Beyond its core product offerings, the company engages in a broad spectrum of related activities, including the design and engineering of facilities, cannabis breeding programs, research and development, and both wholesale and retail distribution channels. For medical users, Aurora provides a diverse selection of products such as different strains of dried cannabis, cannabis oils, capsules, and topical kits. Their inventory also includes ancillary items like vaporizers, vaporizer accessories, herb mills (specifically for CanniMed products), grinders, and secure containers for vaporizers. The company is actively involved in developing advanced medical cannabis products, with ongoing work on oral, topical, edible, and inhalable formulations. Furthermore, Aurora manages CanvasRX, a network of centers dedicated to cannabis counseling and community outreach. Its service portfolio extends to providing patient support, specialized design and construction services, and comprehensive analytical testing for cannabis products. Aurora Cannabis Inc. manages an extensive collection of brands, including Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. The company's main corporate office is located in Edmonton, Canada.

        CEO
        Miguel Martin
        Employees
        1.03K
        Beta
        1.35

        Explore

        Frequently asked questions

        What is the intrinsic value of Aurora Cannabis Inc. (ACB)?

        Aurora Cannabis Inc. (ACB) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ACB undervalued?

        ACB trades at a price of $4.16 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.